871902-99-7

Upstream product

• 89364-31-8 3-tetrahydrofuroic acid 
• 717923-55-2 C₂₉H₃₄F₆N₄O 
• 785-56-8 3,5-bis(trifluoromethyl)phenyl carboxylic acid chloride 
• 190964-86-4 (+/-)-1-[3,5-bis-(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinone 
• 717927-37-2 (+)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinone 
• 681291-90-7 C₂₃H₂₁F₆NO₃ 
• 681291-91-8 (+)-(2R-trans)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-(phenylmethyl)-1-piperazinyl]piperidine 
• 717923-54-1 C₃₆H₄₀F₆N₄O 
• 193201-63-7 (±)-7-(phenylmethyl)-1,4-dioxa-8-azaspiro[4.5]decane 

Relevant academic research and scientific papers

(2-BENZYL-4-{4-[1-(TETRAHYDROFURAN-3-CARBONYL)-PYRROLIDIN-3-YL]-PIPERAZIN-1-YL}-PIPERIDIN-1-YL)-(3,5-TRIFLUOROMETHYL-PHENYL))-METHANONE FOR THE TREATMENT OF SCHIZOPHRENIA

This invention concerns the use of 2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin- l -yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl)-methanone and its derivatives having neurokinin antagonistic activity, in particular a combine